Humanized cobra venom factor: Experimental therapeutics for targeted complement activation and complement depletion

Current Pharmaceutical Design

Volumn 13, Issue 28, 2007, Pages 2916-2926

  Vogel, Carl Wilhelm ^a   Fritzinger, David C ^a  

^a UNIVERSITY OF HAWAII CANCER CENTER   (United States)

Author keywords

Alternative pathway; C3 convertase; Cobra venom factor; Complement; Complement depletion; Complement inhibition; Complement system; CVF; Protein humanization

Indexed keywords

ANAPHYLATOXIN; ANTIBODY CONJUGATE; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C5; COMPLEMENT INHIBITOR; DIRECT LYTIC FACTOR; HC 31348; HC 31496; HC 31498; HC 31504; HC 31550; HYBRID PROTEIN; IMMUNOGLOBULIN ANTIBODY; RECOMBINANT COMPLEMENT COMPONENT C3; RECOMBINANT DIRECT LYTIC FACTOR; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG; COBROTOXIN; COMPLEMENT; SNAKE VENOM;

ACUTE GRAFT REJECTION; ALLERGIC ENCEPHALOMYELITIS; ALZHEIMER DISEASE; ANTIBACTERIAL ACTIVITY; ANTIPHOSPHOLIPID SYNDROME; ASTHMA; AUTOIMMUNE HEMOLYTIC ANEMIA; BIOLOGICAL ACTIVITY; BURN; CIRCULAR DICHROISM; COMPLEMENT SYSTEM; DNA SEQUENCE; DRUG DESIGN; DRUG STRUCTURE; DRUG TARGETING; ENZYME KINETICS; GENETIC SIMILARITY; GLOMERULONEPHRITIS; HEART MUSCLE ISCHEMIA; HUMAN; IMMUNOGENICITY; IMMUNOREACTIVITY; MOLECULAR CLONING; MULTIPLE SCLEROSIS; MYASTHENIA GRAVIS; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PATHOGENESIS; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN INTERACTION; PROTEIN PROTEIN INTERACTION; PROTEIN PURIFICATION; PROTEIN STABILITY; PROTEIN STRUCTURE; PROTEIN SYNTHESIS; REPERFUSION INJURY; REVIEW; RHEUMATOID ARTHRITIS; SEPTIC SHOCK; SEQUENCE HOMOLOGY; STROKE; ANIMAL; CHEMISTRY; COMPLEMENT ACTIVATION; DRUG DELIVERY SYSTEM; DRUG EFFECT; METABOLISM; METHODOLOGY; PHYSIOLOGY;

ANIMALS; COBRA VENOMS; COMPLEMENT ACTIVATION; COMPLEMENT SYSTEM PROTEINS; DRUG DELIVERY SYSTEMS; HUMANS;

EID: 38449097109     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161207782023748     Document Type: Review

References (126)

1. Campbell RD, Law SK, Reid KB, Sim RB. Structure organization and regulation of the complement genes. Annu Rev Immunol 1988, 6: 161-95.
2. Carroll MC. The complement system in B cell regulation. Mol Immunol 2004; 41: 141-6.
3. Fujita T, Matsushita M, Endo Y. The lectin-complement pathway its role in innate immunity and evolution. Immunol Rev 2004; 198: 185-202.
4. Holers VM. Phenotypes of complement knockouts. Immunopharmacology 2000; 49: 125-31.
5. Holers VM, Thurman JM. The alternative pathway of complement in disease: opportunities for therapeutic targeting. Mol Immunol 2004; 41: 147-52.
6. Köhl J. Anaphylatoxins and infectious and non-infectious inflammatory diseases. Mol Immunol 2001; 38: 175-87.
7. Law SKA, Reid KBM. Complement IRL Press: Oxford OX England; Washington-DC 1988.
8. Lutz HU, Jelezarova E. Complement amplification revisited. Mol Immunol 2006; 43: 2-12.
9. Mollnes TE, Lachmann PJ. Regulation of complement. Scand J Immunol 1988; 27: 127-42.
10. Morgan BP, Harris CL. Complement regulatory proteins Academic Press: San Diego 1999.
11. Müller-Eberhard HJ. Molecular organization and function of the complement system. Annu Rev Biochem 1988; 57: 321-47.
12. Petersen SV, Thiel S, Jensenius JC. The mannan-binding lectin pathway of complement activation: biology and disease association. Mol Immunol 2001; 38: 133-49.
13. Rother K, Till GO, Hänsch GM. The complement system Springer: Berlin; New York 1998.
14. Sjöholm AG, Jönsson G, Braconier JH, Sturfelt G, Truedsson L. Complement deficiency and disease: an update. Mol Immunol 2006; 43: 78-85.
15. Smith GP, Smith RA. Membrane-targeted complement inhibitors. Mol Immunol 2001; 38: 249-55.
16. Thurman JM, Holers VM. The central role of the alternative complement pathway in human disease. J Immunol 2006; 176: 1305-10.
17. Turnberg D, Botto M. The regulation of the complement system: insights from genetically-engineered mice. Mol Immunol 2003; 40: 145-53.
18. Walport MJ. Complement. First of two parts. N Engl J Med 2001; 344: 1059-66.
19. Walport MJ. Complement. Second of two parts. N Engl J Med 2001; 344: 1140-4.
20. Ziccardi RJ, Cooper NR. In Cytolytic Lymphocytes and Complement: Effector of the Immune System E.R. Podack ed, CRC Press: Boca Raton FL 1988; 1: 21-40.
21. Vogel C-W. In Handbook of Natural Toxins: Reptile and Amphibian Venoms. Tu AT Ed, Marcel Dekker: New York 1991; 5: 147-88.
22. Vogel C-W, Bredehorst R, Fritzinger DC, Grunwald T, Ziegelmüller P, Kock MA. Structure and function of cobra venom factor the complement-activating protein in cobra venom. Adv Exp Med Biol 1996; 391: 97-114.
23. Wüster W. Taxonomic changes and toxinology: systematic revisions of the Asiatic cobras (Naja naja species complex). Toxicon 1996; 34: 399-406.
24. Flexner S, Noguchi H. Snake venom in relation to haemolysis bacteriolysis and toxicity. J. Exp. Med. 1903; 6: 277-301.
25. Friedberger E, Mita S, Kumagai T. Die Bildung eines akut wirkenden Giftes (Anaphylatoxin) aus Toxinen (Tetanus Diphtherie Schlangengift). Z. Immunitäsforsch 1913; 17: 506-538.
26. Götze O, Müller-Eberhard HJ. The alternative pathway of complement activation. Adv Immunol 1976; 24: 1-35.
27. Ballow M, Cochrane CG. Two anticomplementary factors in cobra venom: hemolysis of guinea pig erythrocytes by one of them. J Immunol 1969; 103: 944-52.
28. Eggertsen G, Lind P, Sjöquist J. Molecular characterization of the complement activating protein in the venom of the Indian cobra (Naja N. siamensis). Mol Immunol 1981; 18: 125-33.
29. Müller-Eberhard HJ, Fjellström KE. Isolation of the anticomplementary protein from cobra venom and its mode of action on C3. J Immunol 1971 107: 1666-72.
30. Vogel C-W, Müller-Eberhard HJ. Cobra venom factor: improved method for purification and biochemical characterization. J Immunol Methods 1984; 73: 203-20.
31. Gowda DC, Schultz M, Bredehorst R, Vogel C-W. Structure of the major oligosaccharide of cobra venom factor. Mol Immunol 1992; 29: 335-42.
32. Grier AH, Schultz M, Vogel C.-W. Cobra venom factor and human C3 share carbohydrate antigenic determinants. J Immunol 1987; 139: 1245-52.
33. Gowda DC, Glushka J, Halbeek H, Thotakura RN, Bredehorst R, Vogel C.-W. N-linked oligosaccharides of cobra venom factor contain novel alpha(1-3)galactosylated Le(x) structures. Glycobiology 2001; 11: 195-208.
34. Gowda DC, Petrella EC, Raj TT, Bredehorst R, Vogel C.-W. Immunoreactivity and function of oligosaccharides in cobra venom factor. J Immunol 1994; 152: 2977-86.
35. Smith CA, Vogel C.-W, Müller-Eberhard H. J. Ultrastructure of cobra venom factor-dependent C3/C5 convertase and its zymogen factor 13 of human complement. J Biol Chem 1982; 257: 9879-82.
36. Vogel C-W, Smith CA, Ml̈ler-Eberhard H. J. Cobra venom factor: structural homology with the third component of human complement. J Immunol 1984; 133: 3235-41.
37. Sharma S, Jabeen T, Singh RK, Bredhorst R, Vogel CW, Betzel C, Singh T. P. Structural studies on the cobra venom factor: isolation purification crystallization and preliminary crystallographic analysis. Acta Crystallogr D Biol Crystallogr 2001; 57: 596-8.
38. Fritzinger DC, Bredehorst R, Vogel C-W. Molecular cloning and derived primary structure of cobra venom factor. Proc Natl Acad Sci USA 1994; 91: 12775-9.
39. de Bruijn MH, Fey GH. Human complement component C3: cDNA coding sequence and derived primary structure. Proc Natl Acad Sci USA 1985; 82: 708-12.
40. Tomana M, Niemann M, Garner C, Volanakis JE. Carbohydrate composition of the second third and fifth components and factors B and D of human complement. Mol Immunol 1985; 22: 107-11.
41. Hase S, Kikuchi N, Ikenaka T, Inoue K. Structures of sugar chains of the third component of human complement. J Biochem (Tokyo) 1985; 98: 863-74.
42. Hirani S, Lambris JD, Müller-Eberhard HJ. Structural analysis of the asparagine-linked oligosaccharides of human complement component C3. Biochem J 1986; 233: 613-6.
43. Janssen BJ, Huizinga EG, Raaijmakers HC, Roos A, Daha MR, Nilsson-Ekdahl K, et al. Structures of complentent component C3 provide insights into the function and evolution of immunity. Nature 2005; 437: 505-11.
44. Brade V, Hall RE, Colten HR. Biosynthesis of pro-C3 a precursor of the third component of complement. J Exp Med 1977; 146: 759-65.
45. Medicus RG, Götze O, Müller-Eberhard HJ. The serine protease nature of the C3 and C5 convertases of the classical and alternative complement pathways. Scand J Immunol 1976; 5: 1049-55.
46. Pangburn MK, Schreiber RD, Müller-Eberhard HJ. Human complement C3b inactivator: isolation characterization and demonstration of an absolute requirement for the serum protein beta1H for cleavage of C3b and C4b in solution. J Exp Med 1977; 146: 257-70.
47. Whaley K, Ruddy S. Modulation of the alternative complement pathways by beta 1 H globulin. J Exp Med 1976; 144: 1147-63.
48. Fritzinger DC, Petrella EC, Connelly MB, Bredehotst R, Vogel C-W. Primary structure of cobra complement component C3. J Immunol 1992; 149 3554-62.
49. Lundwall Å, Hellman U, Eggertsen G, Sjöquist J. Chemical characterization of cyanogen bromide fragments from the beta-chain of human complement factor C3. FEBS Lett 1984; 169: 57-62.
50. Eggertsen G, Lundwall A, Hellman U, Sjöquist J. Antigenic relationships between human and cobra complement factors C3 and cobra venom factor (CVF) from the Indian cobra (Naja naja). J Immunol 1983; 31: 1920-3.
51. Bambai B, Teppke M, Bredehorst R, Vogel C-W. cDNA Cloning and Expression of Cobrin the C3-Cleaving Metalloprotease from Cobra Venom. Mol Immunol 1998; 35: 408.
52. O'Keefe MC, Caporale LH, Vogel C-W. A novel cleavage product of human complement component C3 with structural and functional properties of cobra venom factor. J Biol Chem 1988; 263: 12690-7.
53. O'Keefe MC, Vogel C.-W, Caporale LH. Characterization of a protease from cobra venom that cleaves the human complement component C3. Fed. Proc. 1984; 43: 1956.
54. Alper CA, Balavitch D. Cobra venom factor: evidence for its being altered cobra C3 (the third component of complement). Science 1976; 191: 1275-6.
55. Vogel C-W, Pangburn MK. An improved statistical method for quantification of similarities of amino acid compositions reveals homologies among complement proteins. Complement 1985; 2: 81.
56. Fritzinger DC, Hew BE; Thorne M, Pangburn MK, Janssen BJ, Gros P, et al. Human C3 Derivatives with Cobra Venom Factor-like Functions for Therapeutic Complement Depletion. Submitted 2006.
57. Fritzinger DC, Hew BE, Pangburn MK, Janssen BJC, Gros P, Vogel C-W. Human C3/Cobra Venom Factor hybrid proteins with potential therapeutic applications, Mol Immunol 2006; 43: 141-2.
58. Bammert H, Fritzinger DC, Bredehorst R, Nonaka M, Voget C-W. A phylogenetic study of the presence of intron 31 in the complement C3 genes of vertebrates. Mol. Immunol 2004; 41: 206.
59. Bammert H, Kunze B, Li Y, Fritzinger DC, Bredehorst R, Vogel C.-W. Structure of the Cobra Venom Factor (CVF) Gene and Comparison with the Human C3 Gene. Intern. Immunopharmacol. 2002; 2: 1275-6.
60. Vik DP, Amiguet P, Moffat GJ, Fey M, Amiguet-Barras F, Wetsel RA, Tack BF. Structural features of the human C3 gene: intron/exon organization transcriptional start site and promoter region sequence. Biochemistry 1991; 30: 1080-5.
61. Hensley P, O'Keefe MC, Spangler CJ, Osborne JC. Jr, Vogel C-W. The effects of metal ions and temperature on the interaction of cobra venom factor and human complement factor B. J Biol Chem 1986; 261: 11038-44.
62. Vogel C-W, Müller-Eberhard HJ. The cobra venom factor-dependent C3 convertase of human complement. A kinetic and thermodynamic analysis of a protease acting on its natural high molecular weight substrate. J Biol Chem 1982; 257: 8292-9.
63. Götze O, Müller-Eberhard HJ. The C3-activator system: an alternate pathway of complement activation. J Exp Med 1971; 134: 90s-108.
64. Lesavre PH, Hugli TE, Esser AF, Müller-Eberhard HJ. The alternative pathway C3/C5 convertase: chemical basis of factor B activation. J Immunol 1979; 123: 529-34.
65. Smith CA, Vogel C-W, Müller-Eberhard HJ. MHC Class III products: an electron microscopic study of the C3 convertases of human complement. J Exp Med 1984; 159: 324-9.
66. Vogt W, Dieminger L, Lynen I, Schmidt G. Alternative pathway for the activation of complement in human serum. Formation and composition of the complex with cobra venom factor that cleaves the third component of complement. Hoppe Seylers Z Physiol Chem 1974; 355: 171-83.
67. DiScipio RG, Smith CA, Müller-Eberhard HJ, Hugli TE. The activation of human complement component C5 by a fluid phase C5 convertase. J Biol Chem 1983; 258: 10629-36.
68. Petrella EC, Wilkie SD, Smith CA, Morgan AC. Jr, Vogel C-W. Antibody conjugates with cobra venom factor. Synthesis and biochemical characterization. J Immunol Methods 1987; 104: 159-72.
69. von Zabern I, Hinsch B, Przyklenk H, Schmidt G, Vogt W. Comparison of Naja n. naja and Naja h. haje cobra-venom factors: correlation between binding affinity for the fifth component of complement and mediation of its cleavage. Immunobiology 1980; 157: 499-514.
70. Daha MR, Fearon DT, Austen KF. C3 requirements for formation of alternative pathway C5 convertase. J Immunol 1976; 117: 630-4.
71. Vogt W, Schmidt G. Hydrolytic activation of the fifth component of complement (C5) by C3 convertases depends on its binding to surface-fixed C3b: Specific interference with binding by properdin Factor B or propamidine leads to inhibition of C5 cleavage and utilization. J Immunol 1978; 120: 1801.
72. Pangburn MK, Müller-Eberhard HJ. The C3 convertase of the alternative pathway of human complement. Enzymic properties of the bimolecular proteinase. Biochem J 1986; 235: 723-30.
73. Fritzinger DC, Hew BE, Pangburn MK, Vogel C.-W. Generation of Human C3 Derivatives with CVF-like function for therapeutic complement depletion. Faseb J. 2005; 19: A324.
74. Hew BE, Thorne M, Fritzinger DC, Vogel C-W. Humanized cobra venom factor (CVF): Generation of Human C3 derivitives with CVF-like function. Mol Immunol 2004; 41: 244.
75. Lachmann PJ, Halbwachs L The influence of C3b inactivator (KAF) concentration on the ability of serum to support complement activation. Clin Exp Immunol 1975; 21: 109-14.
76. Nagaki K, Iida K, Okubo M, Inai S. Reaction mechanisms of beta1H globulin. Int Arch Allergy Appl Immunol 1978; 57: 221-32.
77. Rawal N, Pangburn MK. Formation of high affinity C5 convertase of the classical pathway of complement. J Biol Chem 2003; 278: 38476-83.
78. Rawal N, Pangburn MK. Functional role of the noncatalytic subunit of complement C5 convertase. J Immunol 2000; 164: 1379-85.
79. Rawal N, Pangburn MK. Structure/function of C5 convertases of complement. Int Immunopharmacol 2001; 1: 415-22.
80. Vogt W, Schmidt G, Von Buttlar B. Factors and conditions essential for the activation of the fifth component of complement and release of anaphylatoxin. Monogr. Allergy 1977; 12: 86-9.
81. Cochrane CG, Müller-Eberhard HJ, Aikin BS. Depletion of plasma complement in vivo by a protein of cobra venom: its effect on various immunologic reactions. J Immunol 1970; 105: 55-69.
82. Maillard JL, Zarco RM. Decomplementization by a factor extracted from cobra venom. Effect on several immune reactions of the guinea pig and rat. Ann Inst Pasteur (Paris) 1968; 114: 756-74.
83. Nelson RA. Jr. A new concept of immunosuppression in hypersensitivity reactions and in transplantation immunity. Surv Ophthalmol 1966; 11: 498-505.
84. Kock MA, Hew BE, Bammert H, Fritzinger DC, Vogel CW. Structure and function of recombinant Cobra Venom factor. J Biol Chem 2004; 279: 30836-43.
85. Vogel CW, Fritzinger DC, Hew BE, Thorne M, Bammert H. Recombinant cobra venom factor. Mol Immunol 2004; 41: 191-9.
86. Kölln J, Spillner E, Andrä J, Klensang K, Bredehorst R. Human C3 derivatives engineered for decomplementation by forming stable C3 convertases. Mol Immunol 2004; 41: 259.
87. Till GO, Morganroth ML, Kunkel R, Ward PA. Activation of C5 by cobra venom factor is required in neutrophil-mediated lung injury in the rat. Am J Pathol 1987; 129: 44-53.
88. Andrä J, Halter R, Kock MA, Niemann H, Vogel C-W, Paul D. Generation and characterization of transgenic mice expressing cobra venom factor. Mol Immunol 2002; 39: 357-65.
89. Wang Y, Rollins SA, Madri JA, Matis LA. Anti-C5 monoclonal antibody therapy prevents collagen-induced arthritis and ameliorates established disease. Proc Natl Acad Sci USA 1995; 92: 8955-9.
90. Buyon JP, Tamerius J, Ordorica S, Young B, Abramson SB. Activation of the alternative complement pathway accompanies disease flares in systemic lupus erythematosus during pregnancy. Arthritis Rheum 1992; 35: 55-61.
91. Cochrane CG. The role of complement in experimental disease models. Springer Semin Immunopathol 1984; 7; 263-70.
92. Kilgore KS, Friedrichs GS, Homeister JW, Lucchesi BR. The complement system in myocardial ischaemia/reperfusion injury. Cardiovasc Res 1994; 28: 437-44.
93. Maroko PR, Carpenter CB, Chiariello M, Fishbein MC, Radvany P, Knostman JD, et al. Reduction by cobra venom factor of myocardial necrosis after coronary artery occlusion. J Clin Invest 1978; 61: 661-70.
94. Weiser MR, Williams JP, Moore FD Jr, Kobzik L, Ma M, Hechtman IIB, et al. Reperfusion injury of ischemic skeletal muscle is mediated by natural antibody and complement. J Exp Med 1996; 183: 2343-8.
95. Dalmasso AP. The complement system in xenotransplantation. Immunopharmacology 1992; 24: 149-60.
96. Piddlesden SJ, Jiang S, Levin JL, Vincent A, Morgan BP. Soluble complement receptor 1 (sCR1) protects against experimental autoimmune myasthenia gravis. J Neuroimmunol 1996; 71: 173-7.
97. Couser WG, Baker PJ, Adler S. Complement and the direct mediation of immune glomerular injury: a new perspective. Kidney Int 1985; 28: 879-90.
98. Rehan A, Wiggins RC, Kunkel RG, Till GO, Johnson KJ. Glomerular injury and proteinuria in rats after intrarenal injection of cobra venom factor. Evidence for the role of neutrophil-derived oxygen free radicals. Am J Pathol 1986; 123: 57-66.
99. Schreiber AD, Frank MM. Role of antibody and complement in the immune clearance and destruction of erythrocytes. I. In vivo effects of IgG and IgM complement-fixing sites. J Clin Invest 1972; 51: 575-82.
100. Hack CE, Voerman HJ, Eisele B, Keinecke HO, Nuijens JH, Eerenberg AJ, et al. C1-esterdse inhibitor substitution in sepsis. Lancet 1992; 339-378.
101. Gallinaro R, Cheadle WG, Applegate K, Polk HC Jr. The role of the complement system in trauma and infection. Surg Gynecol Obstet 1992; 174: 435-40.
102. Huang J, Kim LJ, Mealey R, Marsh HC Jr, Zhang Y, Tenner AJ, et al. Neuronal protection in stroke by an sLex-glycosylated complement inhibitory protein. Science 1999; 285: 595-9.
103. Rogers J, Cooper NR, Webster S, Schultz J, McGeer PL, Styren SD, et al. Complement activation by beta-amyloid in Alzheimer disease. Proc Natl Acad Sci USA 1992; 89: 10016-20.
104. Regal JF, Fraser DG, Anderson DE, Solern LE. Enhancement of antigen-induced bronchoconstriction after intravascular complement activation with cobra venom factor. Reversal by granulocyte depletion. J Immunol 1993; 150: 3496-505.
105. Davoust N, Nataf S, Reiman R, Holers MV, Campbell IL, Barnum SR. Central nervous system-targeted expression of the complement inhibitor sCrry prevents experimental allergic encephalomyelitis. J Immunol 1999; 163: 6551-6.
106. Williams KC, Ulvestad E, Hickey WF. Immunology of multiple sclerosis. Clin Neurosci 1994; 2: 229-45.
107. Sahu A, Lambris JD. Complement inhibitors: a resurgent concept in anti-inflammatory therapeutics. Immunopharmacology 2000; 49: 133-48.
108. Vogel C-W. In Immunoconjugates. Antibody Conjugates in Radioimaging and Therapy of Cancer C.-W. Vogel ed, Oxford University Press: New York 1987; pp. 170-88.
109. Vogel CW, Müller-Eberhard HJ. Induction of immune cytolysis: tumor-cell killing by complement is initiated by covalent complex of monoclonal antibody ind stable C3/C5 convertase. Proc Natl Acad Sci USA 1981; 78: 7707-11.
110. Vogel CW, Wilkie SD, Morgan AC. In vivo studies with covalent conjugates of cobra venom factor and monoclonal, antibodies to human tumors. Haematol Blood Transfus 1985; 29: 514-7.
111. Müller B, Müller-Ruchholtz W. Covalent conjugates of monoclonal antibody and cobra venom factor mediate specific cytotoxicity via alternative pathway of human complement activation. Leuk Res 1987; 11: 461-8.
112. Juhl H, Petrella EC, Cheung NK, Bredehorst R, Vogel C-W. Complement killing of human neuroblastoma cells: a cytotoxic monoclonal antibody and its F(ab')2-cobra venom factor conjugate are equally cytotoxic. Mol Immunol 1990; 27: 957-64.
113. Juhl H, Petrella EC, Cheung NK, Bredehorst R, Vogel C-W. Additive cytotoxicity of different monoclonal antibody-cobra venom factor conjugates for human neuroblastoma cells. Immunobiology 1997; 197: 444-59.
114. Parker CJ, White VF, Falk RJ. Site-specific activation of the alternative pathway of complement. Complement 1986; 3: 223-35.
115. Zara J, Pomato N, McCabe RP, Bredehorst R, Vogel CW. Cobra venom factor immunoconjugates: effects of carbohydrate-directed versus amino group-directed conjugation. Bioconjug Chem 1995; 6: 367-72.
116. Vogel C-W, Bredehorst R. In Encyclopedia of Human Biology 2nd edition R. Dulbecco ed, Academic Press: San Diego 1997; 4: 723-37.
117. Juhl H, Sievers M, Baltzer K, Helmig F, Wolf H, Brenner W, et al. A monoclonal antibody-cobra venom factor conjugate increases the tumor-specific uptake of a 99mTc-labeled anti-carcinoembryonic antigen antibody by a two-step approach. Cancer Res 1995; 55: 5749s-55.
118. Mollnes TE, Kirschfink M. Strategies of therapeutic complement inhibition. Mol Immunol 2006; 43: 107-21.
119. Morgan BP, Harris CL. Complement therapeutics; history and current progress. Mol Immunol 2003; 40: 159-70.
120. Hebell T, Ahearn JM, Fearon DT. Suppression of the immune response by a soluble complement receptor of B lymphocytes. Science 1991; 254: 102-5.
121. Grunwald T, Ziegelmüller P, Ollert MW, Bredehorst R, Vogel C.-W. Cobra Venom Factor: An intact β-chain is not required for activity. Mol. Immunol 1993; 30: 13.
122. Ollert MW, Ziegelmüller P, Grunwald T, Bredehorst R, Vogel C.-W, Protease-derivatized CVF. U.S. Patent 1998# 5714344.
123. Fritzinger DC, Hew BE, Thorne M, Vogel C-W. Functional characterization of cobra venom factor/cobra C3 hybrid proteins. Mol. Immunol 2004; 41: 230.
124. Wehrhahn D, Meiling K, Fritzinger DC, Bredehorst R, Andrä J, Vogel C-W. Analysis of the Structure/Function Relationship of Cobra Venom Factor (CVF) and C3: Generation of CVF/CobraC3 Hybrid Proteins. Immunopharmacology 2000; 49: 94.
125. Kölln J, Bredehorst R, Spillner E. Engineering of human complement component C3 for catalytic inhibition of complement. Immunol Lett 2005; 98: 49-56.
126. Kölln J, Spillner E, Andrä J, Klensang K, Bredehorst R. Complement inactivation by recombinant human C3 derivatives. J Immunol 2004; 173: 5540-5.